These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 4681847)

  • 1. Effectiveness of antitumor agents administered subcutaneously to L1210 leukemic mice in silicone rubber devices.
    Neil GL; Scheidt LG; Kuentzel SL; Moxley TE
    Chemotherapy; 1973; 18(1):27-40. PubMed ID: 4681847
    [No Abstract]   [Full Text] [Related]  

  • 2. Enhancement by tetrahydrouridine of 1-beta-D-arabinofuranosylcytosine (cytarabine) oral activity in L1210 leukemic mice.
    Neil GL; Moxley TE; Manak RC
    Cancer Res; 1970 Aug; 30(8):2166-72. PubMed ID: 4990003
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluation of antileukemic agents in advanced leukemia L1210 in mice. X.
    Kline I; Gang M; Tyrer DD; Venditti JM; Artis EW; Goldin A
    Cancer Chemother Rep 2; 1972 Nov; 3(1):1-69. PubMed ID: 4660732
    [No Abstract]   [Full Text] [Related]  

  • 4. Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules.
    Skipper HE; Schabel FM; Mellett LB; Montgomery JA; Wilkoff LJ; Lloyd HH; Brockman RW
    Cancer Chemother Rep; 1970 Dec; 54(6):431-50. PubMed ID: 5527023
    [No Abstract]   [Full Text] [Related]  

  • 5. Sequential administration of two oncostatic drugs: study of modalities for pharmacodynamic potentiation.
    Pouillart R; Huong TH; Brugerie E; Lheritier J
    Biomedicine; 1974 Dec; 21(12):471-9. PubMed ID: 4462870
    [No Abstract]   [Full Text] [Related]  

  • 6. A comparison of a new nitrosourea derivative, 1-(2-chloroethyl)-3-isobutyl-3-(beta-maltosyl)-1-nitrosourea with various antitumor agents with respect to therapeutic ratios in L1210 leukemia systems.
    Fujimoto S; Ogawa M
    J Pharmacobiodyn; 1987 Jul; 10(7):341-5. PubMed ID: 3694427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous cancer chemotherapy: nitrosourea diffusion through implanted silicone rubber capsules.
    Schmidt V; Zapol W; Prensky W; Wonders T; Wodinsky I; Kitz R
    Trans Am Soc Artif Intern Organs; 1972; 18(0):45-53. PubMed ID: 4679901
    [No Abstract]   [Full Text] [Related]  

  • 8. [Effects of combination chemotherapy of MCNU with various anti-cancer agents].
    Machida S; Ito Y; Hoshino A
    Gan To Kagaku Ryoho; 1985 Feb; 12(2):298-302. PubMed ID: 3918506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response of lymphoid leukemia L1210 in mice to implantable sustained release cytosine arabinoside capsules.
    Fu JC; Khwaja T; Moyer DL; Cummings L; Varvan J; Elshire D
    J Surg Oncol; 1978; 10(1):1-7. PubMed ID: 628213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [L 1210 leukemia, an experimental model for the potentiation of drugs used for acute leukemias].
    Pouillart P; Huong TH; Lhéritier J
    Bull Cancer; 1974; 61(4):509-26. PubMed ID: 4458834
    [No Abstract]   [Full Text] [Related]  

  • 11. The effect of dose interval on the survival of L1210 leukemic mice treated with DNA synthesis inhibitors.
    Neil GL; Homan ER
    Cancer Res; 1973 Apr; 33(4):895-901. PubMed ID: 4696483
    [No Abstract]   [Full Text] [Related]  

  • 12. Dose-related synergism of cytosine arabinoside and methotrexate against murine leukemia L1210.
    Avery TL; Roberts D
    Eur J Cancer (1965); 1974 Jul; 10(7):425-9. PubMed ID: 4457345
    [No Abstract]   [Full Text] [Related]  

  • 13. Therapeutic synergism elicited by the combination of 6-thioguanine and 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitrosourea hydrochloride: synergistic cytocidal activity against L1210 cells in vitro.
    Fujimoto S; Ogawa M
    Gan; 1980 Oct; 71(5):659-66. PubMed ID: 6939645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of dihydrofolate reductase as a signal for scheduling optimal treatment with antileukemic agents.
    Hardesty CT; Chen D; Mead JA
    Cancer Res; 1972 Mar; 32(3):458-61. PubMed ID: 5061301
    [No Abstract]   [Full Text] [Related]  

  • 15. Circadian optimization of the treatment of L1210 leukemia with 1-beta-D-arabinofuranosylcytosine, cyclophosphamide, vincristine and methylprednisolone.
    Burns ER; Scheving LE
    Chronobiologia; 1980; 7(1):41-51. PubMed ID: 7438892
    [No Abstract]   [Full Text] [Related]  

  • 16. Antitumor effect of 1-beta-D-arabinofuranosylcytosine 5'-adamantoate (NSC 117614) in L1210 leukemic mice.
    Neil GL; Wiley PF; Manak RC; Moxley TE
    Cancer Res; 1970 Apr; 30(4):1047-54. PubMed ID: 5504347
    [No Abstract]   [Full Text] [Related]  

  • 17. [Action of nitrosoalkylureas and the longevity of tumor-bearing animals].
    Krutova TV; Kondradov AA; Ostrovskaia LA
    Izv Akad Nauk SSSR Biol; 1983; (6):843-50. PubMed ID: 6655115
    [No Abstract]   [Full Text] [Related]  

  • 18. Enhanced antitumor effect of cytosine arabinoside given in a schedule dictated by kinetic studies in vivo.
    Young RC; Goldberg D; Schein PS
    Biochem Pharmacol; 1973 Jan; 22(2):277-80. PubMed ID: 4763256
    [No Abstract]   [Full Text] [Related]  

  • 19. Formulation of three nitrosoureas for intravenous use.
    Davignon JP; Yang KW; Wood HB; Cradock JC
    Cancer Chemother Rep 3; 1973 May; 4(3):7-11. PubMed ID: 4201309
    [No Abstract]   [Full Text] [Related]  

  • 20. The experimental antitumour properties of three congeners of the acridylmethanesulphonanilide (AMSA) series.
    Cain BF; Atwell GJ
    Eur J Cancer (1965); 1974 Aug; 10(8):539-49. PubMed ID: 4463003
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.